In a report released today, James Shin from Wells Fargo maintained a Buy rating on Alaunos Therapeutics (TCRT – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $0.60.
According to TipRanks, Shin is an analyst with an average return of -20.1% and a 25.00% success rate. Shin covers the Healthcare sector, focusing on stocks such as Alaunos Therapeutics, Iovance Biotherapeutics, and Affimed.
Alaunos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.43.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.01 and a one-year low of $0.41. Currently, Alaunos Therapeutics has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More on TCRT:
- Alaunos Therapeutics reports Q4 EPS (4c), consensus (7c)
- Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
- Alaunos Therapeutics expects cash to fund operations into Q4 2023
- Alaunos Therapeutics highlights anticipated portfolio milestones for 2023
